How ready is RWE for EU Joint Clinical Assessment? Assessing the evidence gaps

The EU Health Technology Assessment Regulation has introduced Joint Clinical Assessment (JCA), a framework for comparing the clinical effectiveness of health technologies across Europe. Real-world evidence (RWE) could help fill gaps where direct trial comparisons are limited, but only if studies are designed with assessors’ methodological expectations in mind.
In this interview, Neil Brett and colleagues from PPD™ Observational Studies and PPD™ Evidera™ Health Economics and Market Access at Thermo Fisher Scientific discuss a gap analysis presented at ISPOR Europe 2026.
The team developed a six-domain JCA-readiness framework based on Regulation (EU) 2021/2282 and HTACG guidance and applied it to 52 recent comparative oncology RWE studies. Their findings identify areas of strong alignment, as well as important gaps in study design, analysis and the applicability of evidence across European settings.
The authors also consider what the first published JCA reports suggest about the use of non-randomized evidence and indirect comparisons.
Read the full interview to explore:
- What JCA-ready RWE looks like in practice
- Why relevant comparators and well-defined outcomes do not necessarily produce credible effect estimates
- How patient-reported outcomes and transferability can be considered during study planning
- Why JCA readiness should be addressed before a study begins
About the interviewees
Neil R. Brett, PhD
Senior Research Scientist, PPD Observational Studies, Thermo Fisher Scientific

Dr Brett has 13+ years of clinical research experience and has spent the past 8 years in his current role designing and overseeing diverse RWE studies including retrospective chart review studies, prospective registries, external comparator arm studies, pregnancy studies and post-authorization safety studies. He has authored more than 50 abstracts and publications on RWE methodology and study outcomes. Dr Brett holds a PhD in Human Nutrition from McGill University.
Garthiga Manickam, PhD
Lead Market Access Writer, PPD Evidera Health Economics and Market Access, Thermo Fisher Scientific

Dr Manickam has 7+ years of experience developing strategic market access communications and evidence-based materials to communicate product value to payers and healthcare decision makers across a range of therapeutic areas, including oncology, rare diseases, endocrinology and metabolic disorders, neurology, and infectious diseases. Her work spans global value dossiers, objection handlers, AMCP dossiers, value stories, HTA submissions, landscape reviews, manuscripts, storyboards, advisory board materials, and workshop materials. Dr Manickam holds a PhD in craniofacial health sciences and a BSc in physiology from McGill University.
K. Jack Ishak (Sahakian), PhD
Vice President, Statistical Methodology and Strategy, PPD Evidera Health Economics and Market Access, Thermo Fisher Scientific

Dr Sahakian leads Methods and Innovation for the PPD Evidera Health Economics & Market Access Team and the company’s AI transformation workstream. He has 20+ years experience advancing statistical science in HEOR and RWE, with a focus on development and application of novel statistical methods. His expertise includes advanced time-to-event modeling and projection, population-adjusted indirect treatment comparisons, modeling effects of changing treatment patterns (e.g., crossover), disease progression and forecasting, and simulation-based approaches to disease modelling and study design. His recent work also spans multilevel network meta-regression, transportability, AI and automation. He also co-developed a Bayesian framework that integrates evidence from multiple sources to quantify the benefits of new treatments for rare diseases and the certainty of those estimates.
Deborah Tallarigo, PhD
Senior Market Access Writer, PPD Evidera Health Economics and Market Access, Thermo Fisher Scientific
Dr Tallarigo contributes to the development of market access communications, including global value dossiers, objection handlers, AMCP dossiers, value stories, and manuscripts. She has experience across a range of therapeutic areas, including rare diseases, oncology, and infectious diseases.
Susan A. Oliveria, ScD, MPH, FISPE
Vice President, Head of Scientific Affairs, PPD Observational Studies, Thermo Fisher Scientific

Dr Oliveria has 30+ years of epidemiology and RWE experience across academic, industry, and research settings. Her work focuses on RWE generation, including peri- and post-approval studies, regulatory use of real-world data, and innovative observational study designs. She is active in leading scientific organizations, including ISPE’s RWE Collaborative SIG, Duke-Margolis RWE Collaborative, and GetReal Institute. In her prior role, she served as practice leader for epidemiology and drug safety, leveraging RWE in regulated use cases and innovative study designs. She has held academic appointments at Memorial Sloan-Kettering, Cornell University Medical School, and New York Medical College. Dr Oliveria received her Doctor of Science from the Harvard School of Public Health.
Roy Mootoosamy, PhD
Senior Director, Value Communications Lead, PPD Evidera Health Economics and Market Access, Thermo Fisher Scientific

Dr Mootoosamy leads the development of market access communications, including value stories, value dossiers and health technology appraisal submissions for multiple markets. He also has experience leading the development of product monographs, value story presentations and objection handlers. His background spans neuroscience research and pharmaceutical law; he completed postdoctoral research on prion disease biology at the Wolfson Centre for Age-Related Diseases and King’s College London, and worked as a scientific specialist at Arnold & Porter (UK) LLP on pharmaceutical product liability and healthcare regulatory matters. Dr Mootoosamy also holds additional degrees in genetics, developmental biology and neuroscience.
Disclaimers
All authors are employees of PPD Observational Studies and PPD Evidera Health Economics & Market Access, Thermo Fisher Scientific. This poster was funded by Thermo Fisher Scientific.
The opinions expressed in this feature are those of the author and do not necessarily reflect the views of The Evidence Base® or Becaris Publishing Ltd.
Sponsorship for this Interview was provided by Thermo Fisher Scientific.
